EyePoint Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

EyePoint PharmaceuticalsDer Gewinn des Unternehmens wird voraussichtlich um 0.4% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 40.7% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 8.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -92.5% betragen.

Wichtige Informationen

-0.4%

Wachstumsrate der Gewinne

8.5%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	22.8%
Wachstumsrate der Einnahmen	40.7%
Zukünftige Eigenkapitalrendite	-92.5%
Analystenabdeckung	Good
Zuletzt aktualisiert	07 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

Jun 19

EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)

May 06

More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

Mar 31

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time

Feb 20

Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

Feb 05

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Jan 29

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

Dec 18

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Dec 13

Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

May 14

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

Apr 17

EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space

Aug 30

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Jul 16

EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD

Jul 15

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Mar 06

EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely

Sep 24

Estimating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Apr 02

How Many EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Do Institutions Own?

Feb 22

EyePoint Pharma announces potential capital raise

Feb 01

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:EYPT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	10	-217	-129	-207	7
12/31/2025	14	-176	-139	-163	10
12/31/2024	44	-125	-125	-125	7
3/31/2024	50	-79	-17	-12	N/A
12/31/2023	46	-71	-2	2	N/A
9/30/2023	43	-100	9	12	N/A
6/30/2023	37	-106	12	14	N/A
3/31/2023	40	-102	-64	-62	N/A
12/31/2022	41	-102	-67	-65	N/A
9/30/2022	42	-78	-71	-69	N/A
6/30/2022	41	-77	-64	-64	N/A
3/31/2022	39	-67	-55	-55	N/A
12/31/2021	37	-58	-50	-50	N/A
9/30/2021	33	-54	-28	-28	N/A
6/30/2021	39	-42	-19	-19	N/A
3/31/2021	34	-44	-14	-13	N/A
12/31/2020	34	-45	-15	-14	N/A
9/30/2020	36	-40	-32	-32	N/A
6/30/2020	23	-52	-48	-48	N/A
3/31/2020	26	-51	-60	-60	N/A
12/31/2019	20	-57	-57	-57	N/A
9/30/2019	14	-58	-56	-56	N/A
6/30/2019	12	-75	-53	-53	N/A
3/31/2019	6	-98	-42	-42	N/A
12/31/2018	5	-86	-34	-33	N/A
9/30/2018	3	-80	-28	-28	N/A
6/30/2018	3	-53	-22	-22	N/A
3/31/2018	3	-25	-20	-20	N/A
12/31/2017	3	-23	N/A	-20	N/A
9/30/2017	8	-17	N/A	-20	N/A
6/30/2017	8	-18	N/A	-20	N/A
3/31/2017	7	-19	N/A	-20	N/A
12/31/2016	7	-19	N/A	-20	N/A
9/30/2016	1	-24	N/A	-18	N/A
6/30/2016	2	-22	N/A	-16	N/A
3/31/2016	2	-20	N/A	-15	N/A
12/31/2015	2	-20	N/A	-15	N/A
9/30/2015	2	-19	N/A	10	N/A
6/30/2015	27	6	N/A	10	N/A
3/31/2015	26	8	N/A	11	N/A
12/31/2014	28	10	N/A	13	N/A
9/30/2014	28	11	N/A	-11	N/A
6/30/2014	3	-13	N/A	-11	N/A
3/31/2014	4	-13	N/A	-11	N/A
12/31/2013	2	-14	N/A	-11	N/A
9/30/2013	2	-13	N/A	-11	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: EYPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: EYPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: EYPT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: EYPTDie Einnahmen des Unternehmens (40.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: EYPTDie Einnahmen des Unternehmens (40.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: EYPT wird voraussichtlich in 3 Jahren unrentabel sein.

EyePoint Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 18%

Price target increased by 28% to US$39.29

Consensus revenue estimates increase by 19%

Consensus revenue estimates increase by 13%

EyePoint Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Price target decreased to US$33.50

Recent updates

EyePoint Pharmaceuticals, Inc. Highlights Duravuyu Clinical and Regulatory Progress and Pipeline Innovation At R&D Day 2024

Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

New major risk - Revenue and earnings growth

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)

Consensus revenue estimates fall by 18%

New major risk - Shareholder dilution

EyePoint Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board

More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

EyePoint Pharmaceuticals, Inc. Announces Management Changes

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time

Executive Vice-Chairman exercised options and sold US$430k worth of stock

Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

EyePoint Pharmaceuticals, Inc. Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Senior VP & Chief Medical Officer exercised options and sold US$621k worth of stock

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Executive Vice-Chairman recently sold US$874k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Executive Vice-Chairman exercised options and sold US$470k worth of stock

EyePoint Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Verona Clinical Trial of Eyp-1901 for the Treatment of Diabetic Macular Edema

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Executive Vice-Chairman recently sold US$415k worth of stock

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $200.000002 million.

Senior VP & Chief Medical Officer notifies of intention to sell stock

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $200.000002 million.

Price target increased by 28% to US$39.29

EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

EyePoint Pharmaceuticals, Inc. Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet Amd Achieving All Primary and Secondary Endpoints

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

EyePoint Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 01, 2023

EyePoint Pharmaceuticals, Inc. Announces Executive Changes

EyePoint Pharmaceuticals, Inc. Reports Positive Masked Safety Update for Lead Product Candidate Eyp-1901 in Ongoing Pavia and Davio 2 Phase 2 Clinical Trials as of September 1, 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

EyePoint Pharmaceuticals, Inc. Announces Interim Masked Safety Data and Patient Baseline Characteristics for EYP-1901

EyePoint Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Consensus revenue estimates increase by 19%

Eyepoint Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Eyepoint Pharmaceuticals Completes Enrollment in Phase 2 Pavia Clinical Trial of Eyp-1901 in Non-Proliferative Diabetic Retinopathy

Consensus revenue estimates increase by 13%

Alimera Sciences, Inc. entered into an agreement to acquire YUTIQ® from EyePoint Pharmaceuticals, Inc. for $82.5 million.

Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

Full year 2022 earnings: EPS misses analyst expectations

EyePoint Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Eyepoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

EyePoint Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 02, 2022

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy

EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD

EyePoint Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

EyePoint Pharmaceuticals, Inc. Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD

EyePoint Pharmaceuticals, Inc. Appoints Karen Zaderej to Board of Directors

Price target decreased to US$33.50

EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors

EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Price target decreased to US$36.00

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint